HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Bergman, A. J. Articles by Paolini, J. F. Search for Related Content PubMed PubMed Citation Articles by Bergman, A. J. Articles by Paolini, J. F. Social Bookmarking                   What's this?

Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients

From Merck Research Laboratories, Rahway, New Jersey, and West Point, Pennsylvania (Dr Bergman, Ms Burke, Mr Larson, Dr Johnson-Levonas, Dr Murphy, Dr Gottesdiener, Dr Paolini); Schering-Plough Research Institute, Kenilworth, New Jersey (Dr Reyderman, Dr Statkevich, Dr Maxwell, Dr Kosoglu); and Christchurch Clinical Studies Trust, Christchurch, New Zealand (Dr Robson).

This open-label, single-period study evaluated the single-dose pharmacokinetics of ezetimibe (EZE) 10 mg in the setting of steady-state cyclosporine (CyA) dosing in renal transplant patients. A single 10-mg dose of EZE was coadministered with the morning dose of CyA (75-150 mg twice a day). Total EZE (sum of unconjugated, parent EZE and EZE-glucuronide; EZE-total) AUC_0-last and C_max were compared to values derived from a prespecified database of healthy volunteers. Geometric mean ratios (90% CIs) for (EZE + CyA)/EZE alone for EZE-total AUC_(0-last) and C_max were 3.41 (2.55, 4.56) and 3.91 (3.13, 4.89), respectively. Compared to healthy controls, EZE-total AUC_(0-last) was 3.4-fold higher in transplant patients receiving CyA; similar exposure levels were seen in a prior multiple-dose study in which EZE 50 mg was administered to healthy volunteers without dose-related toxicity. Because the long-term safety implications of both higher EZE exposures and undetermined effect on CyA are not yet understood, the clinical significance of this interaction is unknown.

Key Words: Ezetimibe • cyclosporine • interaction • renal • transplant

Address for reprints: Arthur J. Bergman, Clinical Drug Metabolism, Merck Research Laboratories, WP 75-100, Sumneytown Pike, PO Box 4, West Point, PA 19486.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Nogueira and M. Weir The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 766 - 785. [Abstract] [Full Text] [PDF]

				R. Krishna, A. Bergman, P. Larson, J. Cote, K. Lasseter, S. Dilzer, A. Wang, W. Zeng, L. Chen, J. Wagner, et al. Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects J. Clin. Pharmacol., February 1, 2007; 47(2): 165 - 174. [Abstract] [Full Text] [PDF]

				S. Oswald, S. Westrup, M. Grube, H. K. Kroemer, W. Weitschies, and W. Siegmund Disposition and Sterol-Lowering Effect of Ezetimibe in Multidrug Resistance-Associated Protein 2-Deficient Rats J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1293 - 1299. [Abstract] [Full Text] [PDF]